anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 μm, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.
BACKGROUND: Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy.
METHODS: Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR.
RESULTS: The mean serum fibronectin level in the patient group was 76.794 ± 66.998ng/ml. Simultaneously, it was 50.486 ± 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 ± 86.1 ng/ml, while it was 44.7 ± 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker.
CONCLUSIONS: The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.
African Americans (AA) with type 2 diabetes (T2DM) have higher prevalence of diabetes, poorer metabolic control (i.e. poorer blood glucose, blood pressure, and lipid control), and greater risk for complications and death compared to White Americans. Hemoglobin A1c (HbA1c) is the primary marker for glycemic control and is a strong independent predictor of development of complications and increased mortality in T2DM. Key self-care behaviors that influence glycemic control (and HbA1c) include diet, physical activity, self-monitoring of blood glucose and medication adherence. Systematic review of multiple randomized clinical trials (RCTs) show that self-care interventions that include diabetes education and skills training are effective in improving metabolic control in diabetes. Recent findings indicate that patients with diabetes, especially ethnic minority patients, prefer telephone-delivered diabetes education to group visits or internet-based education. Multiple RCTs have documented the effectiveness of telephone-delivered self-care interventions in T2DM. Preliminary data from our group also suggest that a culturally-tailored telephone-delivered diabetes education and skills training intervention is an effective strategy to improve metabolic control in AA patients with T2DM.

This study provides a unique opportunity to address gaps in the literature by testing the efficacy of a technology-intensified diabetes education/skills training (TIDES) intervention in AAs with poorly controlled T2DM. The long-term goal of the project is to identify effective strategies to improve metabolic control and hence reduce diabetes complications and mortality rates in AAs with T2DM.
Radiologists see a "score" from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions.
A recombinant expression system for the expression of a poly amino acid, peptide or protein is provided. The poly amino acid of interest is expressed as a fusion protein that includes an amino acid sequence recognized and cleaved by a Ulpl protease. The amino acid sequence joined to the poly amino acid of interest is preferably from a SUMO (small ubiquitin-like molecule) protein. This sequence imparts favorable solubility and refolding properties to the fusion protein. A purification tag may also be incorporated into the fusion protein for ease of isolation. The Ulpl protease used to cleave the fusion protein may be the Ulpl prtease or the active Ulpl (403-621). The Ulpl protease rapidly and specifically cleaves the fusion proteins of the invention at the Ulpl cleavage site. The amino acid sequence recognized by a Ulpl protease is cleaved asymetrically to leave only an N-terminal serine joined to the poly amino acid of interest: This recombinant expression system is particularly advantagious for expression and rapid and highly specific cleavage and purification of poly amino acids that have low solubilities or are difficult to express in other systems.
Participants randomly assigned to the face-to-face group will use the physical therapy clinic to do the exercises controlled by the principal investigator. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the protocol works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
Ethylene diamine derivatives of the general formula R1R2N.CHR3.CHR4.NR5R6 (wherein R1 stands for a tertiary alkyl radical, R2, R3, R4 and R5 each represent a hydrogen atom or a C1-4 alkyl radical and R6 stands for an alkyl or alkenyl radical of not more than 10 carbon atoms) may be prepared by: (a) the interaction of an amine R5R7NH with a reactive ester (e.g. a halide, sulphate, or alkyl or aryl-sulphonate) of an amino alcohol R8R2N.CHR3.CHR4.OH (wherein R2, R3, R4 and R5 have the above stated meanings, one of R7 and R8 stands for an alkyl or alkenyl radical of not more than 10 carbon atoms and the other stands for a tertiary alkyl radical); (b) the reductive alkylation of a compound R1\R9N.CHR3.CHR4.NR6R10 (wherein R1, R3, R4 and R6 have the above stated meanings and one of R9 and R10 stands for hydrogen and the other for hydrogen or a C1-4 alkyl radical) in the presence of a reducing agent and an aliphatic aldehyde, e.g. formic acid and formaldehyde (for compounds wherein R2 and R5 stand for the same or different C1-4 alkyl radicals); and (c) (for compounds in which the group NR1R2 and NR5R6 are the same) by the interaction of an amine R1R2NH with a reactive ester (e.g. a halide, sulphate, or alkyl-or aryl-sulphonate) of a dihydroxyalkane HO.CHR3.CHR4OH in the presence of an acid binding agent.  Specific examples relate to the preparation of N1-s-butyl-N2-t-butyl-N1, N2- dimethylethylene diamine (dihydrochloride) and N1-t-buty-N1,N2- dimethyl-N2 isopropylethylene diamine (dihydrochloride) by treatment with formic acid and formalin of N1-s-butyl-N2-t-butyl-ethylenediamine and N1-tbutyl-N2- isopropylethylenediamine respectively, these compounds being prepared by the reaction sequence: t-butylamine and ethylenechlorhydrin are heated together to give 2-t-butyl-aminoethanol which is converted to the hydrochloride with dry HCl and reacted wih thionyl chloride to give 2-t-butylaminoethyl chloride (hydrochloride) which is reacted with s-butylamine or isobutylamine to give the dihydrochlorides of the above compounds.ALSO:Pharmaceutical anti-mycobacterial compositions comprise a carrier and one or more compounds of the general formula R1R2N.CHR3.CHR4.NR5R6 wherein R1 represents a tertiary alkyl radical (preferably having up to 10 carbon atoms), R2, R3, R and R5 each represent a hydrogen atom or a C1-4 alkyl radical and R6 represents an alkyl or alkenyl radical having up to 10 carbon atoms.  Ethanol/aceton solutions of N1,N2-di-t-butyl ethylenediamine hydrochloride are specifically excluded.  The compositions may be in any conventional form suitable for oral, parenteral and topical application and may optionally include other agents useful in the treatment of mycobacterial infections, e.g. isonicotinic acid hydrazide, streptomycin, p-aminosalicylic acid and diaminodiphenylsulphone.
PURPOSE: To obtain a readily applicable preparation for external application of an antiseptic agent and/or an agent for promoting the healing of wounds, containing a liposome preparation and capable of sustaining release and topical actions of an active agent. CONSTITUTION: This preparation for external application contains a liposome preparation obtained by sealing most of at least one of an antiseptic agent (e.g. povidone-iodine) and/or an agent for promoting the healing of wounds (e.g. allantoin) in the interior of the liposome as an active ingredient. The liposome has a uniform size of about 20 to about 20,000 nm, most preferably about 1,000 nm. The preparation can be formulated into a form such as a solution, a dispersion, a lotion, a cream, an ointment or a gel. When the liposome preparation especially contains the povidone-iodine, the preparation is effective against infectious diseases in the front of eyes, e.g. viral conjunctivitis.
Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
OBJECTIVE: The objective of this study was to assess the prognostic value of clinical factors and metabolic parameters measured using fluorodeoxyglucose PET (FDG-PET/CT) in predicting disease recurrence, as well as distant metastasis-free survival (DMFS), local recurrence-free survival (LRFS), and overall survival (OS) in patients with uterine cervical cancer who received definitive chemoradiotherapy.
METHODS: The clinical data and FDG-PET parameters, including standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of 194 patients with biopsy-confirmed squamous cell carcinoma of cervical cancer were retrospectively analyzed. Univariate and multivariate analyses were used to ascertain prognostic factors associated with DMFS, LRFS, and OS.
RESULTS: With a median follow-up of 12.5 years, 96 patients (49.5%) presented with disease recurrence, at a median of 9.9 months after chemoradiotherapy. Patients who experienced recurrence had significantly higher values for all FDG-PET parameters compared to patients who did not. In multivariate regression analysis, lymph node metastasis, MTV, and SUV mean were significantly correlated with distant metastasis, while local recurrence was only predicted by SUV max . Lymph node metastasis, high MTV, SUV mean , and TLG predicted shorter DMFS, while only the primary tumor SUV max predicted LRFS. Age, regional nodal metastasis, and higher MTV independently predicted shorter OS in multivariate analysis.
CONCLUSION: We found that metabolic parameters derived from FDG-PET/CT could serve as surrogates for disease recurrence in patients with cervical cancer who were treated with definitive chemoradiotherapy. Patients at high risk of distant metastasis could be defined using SUV mean and MTV, and for local recurrence, by using SUV max .
In a 104-week carcinogenicity study in rats at doses up to 120 mg/kg/day, which is approximately 90 times clinical exposure on a mg/m2 basis, the incidences of benign adenomas of the thyroid and liver were increased in male rats. No evidence of carcinogenicity was found in female rats. The higher incidences of thyroid and liver tumors in male rats were not seen at lower dose of 30 mg/kg/day and 60 mg/kg/day respectively (which are over 20 and 45 times, respectively, clinical exposures on a mg/m2 basis). In a 104-week carcinogenicity study in mice at doses up to 500 mg/kg/day, no evidence of carcinogenicity was found in mice (which is approximately 187 times clinical exposure on a mg/m2 basis). 

Repaglinide was non-genotoxic in a battery of in vivo and in vitro studies: Bacterial mutagenesis (Ames test), in vitro forward cell mutation assay in V79 cells (HGPRT), in vitro chromosomal aberration assay in human lymphocytes, unscheduled and replicating DNA synthesis in rat liver, and in vivo mouse and rat micronucleus tests. 

In a rat fertility study, repaglinide was administered to male and female rats at doses up to 300 and 80 mg/kg/day, respectively. No adverse effects on fertility were observed (which are over 60 times clinical exposure on a mg/m2 basis).
Spaceflight can change metabolic, immunological, and biological homeostasis and cause skin rashes and irritation, yet the molecular basis remains unclear. To investigate the impact of short-duration spaceflight on the skin, we conducted skin biopsies on the Inspiration4 crew members before (L-44) and after (R + 1) flight. Leveraging multi-omics assays including GeoMx™ Digital Spatial Profiler, single-cell RNA/ATAC-seq, and metagenomics/metatranscriptomics, we assessed spatial gene expressions and associated microbial and immune changes across 95 skin regions in four compartments: outer epidermis, inner epidermis, outer dermis, and vasculature. Post-flight samples showed significant up-regulation of genes related to inflammation and KRAS signaling across all skin regions. These spaceflight-associated changes mapped to specific cellular responses, including altered interferon responses, DNA damage, epithelial barrier disruptions, T-cell migration, and hindered regeneration were located primarily in outer tissue compartments. We also linked epithelial disruption to microbial shifts in skin swab and immune cell activity to PBMC single-cell data from the same crew and timepoints. Our findings present the inaugural collection and examination of astronaut skin, offering insights for future space missions and response countermeasures.
A dermatological treatment and composition therefor are described for periodic and effective maintenance of a skin peel patient's subsequent skin condition. The treatment does not use radiation, can be performed quickly, is readily controlled by visual observation of the applied composition, and is self-limiting. The method includes forming a composition having a visualizing agent, a surfactant and an acid or acid equivalent dispersed in a carrier liquid, the concentration of the last not exceeding 30 %; applying the composition to a predetermined area of the patient's skin in a quantity effective to result in a predetermined degree of mild exfoliation of the skin; determining degree of coverage of the area of skin by visual observation of extent of the visualizing agent; and maintaining the composition in contact with the area of skin for a period of time effective to result in the predetermined degree of exfoliation of the skin. Compositions of this type are also disclosed. Preferably, the acid or acid equivalent will be trichloroacetic acid and the surfactant will be a saponin or complex of saponins, preferably steroid saponins. The concentrations of the three principal ingredients, the amount of the composition used and the length of time of the application and treatment will vary according to the specific depth of peel or degree of maintenance which the dermatologist believes appropriate for a particular patient.
Prior to initiating testosterone enanthate injection, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.

Dosage and duration of therapy with testosterone enanthate injection will depend on age, sex, diagnosis, patient’s response to treatment, and appearance of adverse effects. When properly given, injections of testosterone enanthate, are well tolerated. Care should be taken to slowly inject the preparation deeply into the gluteal muscle, being sure to follow the usual precautions for intramuscular administration, such as the avoidance of intravascular injection (see PRECAUTIONS).

In general, total doses above 400 mg per month are not required because of the prolonged action of the preparation. Injections more frequently than every two weeks are rarely indicated. NOTE: Use of a wet needle or wet syringe may cause the solution to become cloudy; however this does not affect the potency of the material. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Testosterone enanthate injection is a clear, colorless to pale yellow solution.

Male hypogonadism: As replacement therapy, i.e., for eunuchism, the suggested dosage is 50 to 400 mg every 2 to 4 weeks.

In males with delayed puberty: Various dosage regimens have been used; some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels. Other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose. Dosage is within the range of 50 to 200 mg every 2 to 4 weeks for a limited duration, for example, 4 to 6 months. X-rays should be taken at appropriate intervals to determine the amount of bone maturation and skeletal development (see INDICATIONS AND USAGE and WARNINGS).

Palliation of inoperable mammary cancer in women: A dosage of 200 to 400 mg every 2 to 4 weeks is recommended. Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease.
For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds - this is a reliable method of sham stimulation as sensations arising from tDCS treatment occur only at the beginning of application as also demonstrated by a randomized study (Gandiga et al. 2006).
BACKGROUND: In infants with complete atrioventricular canal (CAVC) defects, post-operative left atrioventricular valve regurgitation (LAVVR) is a known major cause of morbidity and mortality and a common indication for re-operation. However, there is scarce data to identify risk factors for poor outcomes. Our study aims to find echocardiographic characteristics that predict post-operative LAVVR at discharge and 1-year follow-up.
METHODS: Retrospective cohort study of patients with initial CAVC repair at our hospital who were followed for 1 year between 2013 and 2022. Patients with major co-morbid conditions were excluded. Serial echocardiograms were reviewed. Anatomic details, quantitative and qualitative measure of LAVVR including the number of regurgitant jets, regurgitant jet length and vena contracta width, and ventricular function were collected. The time points measured include pre-operative transthoracic echocardiogram (TTE), post-operative transesophageal echocardiogram (PO-TEE), routine protocol based post-operative day 1 (POD1) TTE, discharge TTE and 1-year post-operative (1yPO) TTE. Paired t-tests, chi-square analysis, and linear regression analysis were performed comparing measured variables to LAVVR outcomes.
RESULTS: Fifty-two patients were included; 92% had Trisomy 21. The majority were classified as Rastelli A (71%), others Rastelli C (29%). Only two patients had moderate or greater LAVVR pre-operatively. The mean age at repair was 125 ± 44 days. Pre-operative LAVVR was the only significant predictor of LAVVR severity at 1 year after backward stepwise regression. Of those with < moderate LAVVR on PO-TEE, 20% had worsening to ≥ moderate at discharge, but only 9% remained that way at 1 year. Of those with ≥ moderate LAVVR on PO-TEE, 40% improved to < moderate by 1 year. Two patients who worsened at 1 year, both secondary to likely cleft suture dehiscence. Only one patient required reoperation in the immediate post-operative period secondary to severe LAVVR due to suture dehiscence. Routine protocol-based POD1 echo did not have any association with altered outcomes.
CONCLUSION: Pre-operative LAVVR was the only significant predictor of LAVVR severity at 1 year. A significant percentage (40%) of patient with ≥ moderate LAVVR on PO-TEE improved to < moderate by 1 year. Furthermore, routine protocol-based POD1 echo did not have any association with altered outcomes.
FIELD: physics.SUBSTANCE: invention relates to personal emergency response means. Profile of a specific client of the PERS is extracted from the database of the PSER. Values of the set of characteristics of said specific PERS client are generated using a computer based on the extracted profile of a specific client of the PERS. Based on the values of the set of characteristics, a prediction of emergency call risk for a specific client of the PERS during a subsequent period of time is calculated using a regression model of risk of an emergency call and generated values of a set of characteristics for a specific client of the PERS by means of a computer. Calculated prediction of emergency call risk is displayed for a particular PERS client on the display element together with the displayed information contained in the profile. One or more incoming requests are received from one or more PERS clients, including a request from said specific PERS client. Prioritizing one or more requests from one or more PERS clients, including a request from said specific PERS client, based on said emergency call risk prediction.EFFECT: technical result consists in reduction of response time to high-risk calls for customer of personal emergency response system (PERS).15 cl, 8 dwg
This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were negative for significant PTSD. They were fitted with open-fit hearing aids that provided mild high-frequency amplification and were monitored for 6 months.